Skip to main content
Top
Published in: Diabetologia 5/2020

Open Access 01-05-2020 | Review

Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study

Authors: Marion M. Mafham, Louise J. Bowman, Richard J. Haynes, Jane M. Armitage

Published in: Diabetologia | Issue 5/2020

Login to get access

Abstract

Reliable assessment of the effects of an intervention usually requires large randomised trials but such studies are becoming increasingly complex and costly to run. ‘Streamlined’ trials are needed in which every aspect of the trial design and conduct is simplified, retaining only those elements needed to answer the research question and ensure the safety of the individual participants. In this review we discuss how the trial ‘A Study of Cardiovascular Events iN Diabetes’ (ASCEND) was streamlined. The study included a two-by-two factorial design: it assessed the effects of low-dose aspirin and, separately, supplementation with n-3 fatty acids on serious vascular events in 15,480 people with diabetes but no overt cardiovascular disease. Other key streamlined design features, such as mail-based recruitment and follow-up, mainly by post, with no in-person visits and use of a run-in period, are also described. We go on to discuss the success of the study and other studies that have employed a similar mail-based approach, and the type of clinical trials that are suitable for mail-based design. Finally, we consider the limitations of the study, and how these could be circumvented in future studies. ASCEND randomised large numbers of eligible participants, achieved good adherence rates and almost complete follow-up at a fraction of the cost of traditional clinic-based trials. Such studies are necessary if researchers are to address the important clinical questions most relevant to improving health.
Literature
7.
go back to reference Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242 Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
14.
go back to reference ASCEND Collaborative Group (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379(16):1529–1539 ASCEND Collaborative Group (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379(16):1529–1539
15.
go back to reference ASCEND Collaborative Group (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379(16):1540–1550 ASCEND Collaborative Group (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379(16):1540–1550
19.
go back to reference Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 321(3):129–135CrossRef Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 321(3):129–135CrossRef
21.
go back to reference Manson JE, Cook NR, Lee IM et al (2019) Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 380(1):23–32 Manson JE, Cook NR, Lee IM et al (2019) Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 380(1):23–32
29.
go back to reference The HPS3/TIMI55–REVEAL Collaborative Group (2017) Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 377:1217–1227CrossRef The HPS3/TIMI55–REVEAL Collaborative Group (2017) Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 377:1217–1227CrossRef
31.
go back to reference Bond S, Payne R, Wilson E et al (2015) Using the UK renal registry for a clinical trial in dialysis patients: the example of SIMPLIFIED. Trials 16(2):A15 (abstract)CrossRef Bond S, Payne R, Wilson E et al (2015) Using the UK renal registry for a clinical trial in dialysis patients: the example of SIMPLIFIED. Trials 16(2):A15 (abstract)CrossRef
36.
go back to reference Wright FL, Green J, Canoy D et al (2012) Vascular disease in women: comparison of diagnoses in hospital episode statistics and general practice records in England. BMC Med Res Methodol 12:161CrossRef Wright FL, Green J, Canoy D et al (2012) Vascular disease in women: comparison of diagnoses in hospital episode statistics and general practice records in England. BMC Med Res Methodol 12:161CrossRef
37.
go back to reference Cosentino F, Grant PJ, Aboyans V et al (2019) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J pii:ehz486 Cosentino F, Grant PJ, Aboyans V et al (2019) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J pii:ehz486
Metadata
Title
Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
Authors
Marion M. Mafham
Louise J. Bowman
Richard J. Haynes
Jane M. Armitage
Publication date
01-05-2020
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 5/2020
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-05049-8

Other articles of this Issue 5/2020

Diabetologia 5/2020 Go to the issue

Up Front

Up Front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.